Completed PHASE2 INTERVENTIONAL 17-arm NCT05289037

COVID-19 Variant Immunologic Landscape Trial (COVAIL Trial)

Phase 2 Clinical Trial to Optimize Immune Coverage of SARS-CoV-2 Existing and Emerging Variants

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions COVID-19

Interventions AS03 BNT162b2 BNT162b2 (B.1.1.529) BNT162b2 (B.1.351) BNT162b2 bivalent (wildtype and Omicron BA.1) BNT162b2 bivalent (wildtype and Omicron BA.4/BA.5) CoV2 preS dTM [B.1.351] CoV2 preS dTM/D614 CoV2 preS dTM/D614+B.1.351 Sodium Chloride, 0.9% mRNA-1273 mRNA-1273.351 mRNA-1273.529 mRNA-1273.617.2

Updated 28 times since 2022 Last updated: Oct 9, 2025 Started: Mar 30, 2022 Primary completion: Nov 22, 2023 Completion: Nov 27, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on COVID-19, this trial is completed. The trial is conducted by National Institute of Allergy and Infectious Diseases (NIAID) and has accumulated 28 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

28 versions recorded

Nov 2025 — Present [monthly]

Completed PHASE2
Sep 2025 — Nov 2025 [monthly]

Completed PHASE2
Apr 2025 — Sep 2025 [monthly]

Completed PHASE2
Sep 2024 — Apr 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2

▶ Show 23 earlier versions

Jun 2024 — Jul 2024 [monthly]

Completed PHASE2
Apr 2024 — Jun 2024 [monthly]

Completed PHASE2

Phase: PHASE1_PHASE2 → PHASE2
Feb 2024 — Apr 2024 [monthly]

Completed PHASE1_PHASE2

Status: Active Not Recruiting → Completed
Jan 2024 — Feb 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2023 — Jan 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2
Nov 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Oct 2023 — Nov 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Sep 2023 — Oct 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Aug 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jul 2023 — Aug 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jun 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
May 2023 — Jun 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Apr 2023 — May 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Mar 2023 — Apr 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Feb 2023 — Mar 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Jan 2023 — Feb 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Active Not Recruiting → Recruiting
Sep 2022 — Nov 2022 [monthly]

Active Not Recruiting PHASE1_PHASE2

Status: Recruiting → Active Not Recruiting
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE1_PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Apr 2022 — May 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Allergy and Infectious Diseases (NIAID)

Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Birmingham, United States , Boston, United States , Chicago, United States , Decatur, United States , Durham, United States , Houston, United States , Iowa City, United States , League City, United States , Mineola, United States and 8 more locations